Results 1 to 10 of about 182,365 (118)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

Translational Oncology, 2021
Purpose: To compare the efficacy and safety of anti-PD1 checkpoint inhibitor plus chemotherapy with anti-PD1 checkpoint inhibitor alone in recurrent and metastatic nasopharyngeal carcinoma (R/M NPC) progressing after first or subsequent-line therapy ...
Qun Zhang, Qi-Feng Jin, Xiao-Zhong Chen   +2 more
exaly   +3 more sources

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

Thoracic Cancer, 2020
The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T‐cells, can attack normal tissues and ...
Hanping Wang, Jiaxin Zhou, Yue Li
exaly   +2 more sources

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis

Frontiers in Cardiovascular Medicine, 2023
BackgroundImmune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early
Xin Zhang, Yi Gan, Haoshuai Zhu, Zhihao Liu, Xiaojing Yao, Chao Cheng, Zhenguo Liu, Chunhua Su, Jianyong Zou   +8 more
doaj   +1 more source

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.

PLoS ONE, 2021
BackgroundImmune checkpoint inhibitors, approved for the treatment of various types of cancer, are known to cause a unique spectrum of side effects, including acute kidney injury (AKI).
Marije S Koks, Gurbey Ocak, Britt B M Suelmann, Cornelia A R Hulsbergen-Veelken, Saskia Haitjema, Marieke E Vianen, Marianne C Verhaar, Karin A H Kaasjager, Meriem Khairoun   +8 more
doaj   +1 more source

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity

Frontiers in Medicine, 2022
Immune checkpoint inhibitors, medications that boost host immune response to tumor cells, are now at the forefront of anti-cancer therapy. While efficacious in the treatment of patients with advanced cancer, immune checkpoint inhibitors can lead to ...
Emily M. Moss, Mark A. Perazella, Mark A. Perazella   +2 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

Kidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy, Sandra M. Herrmann, Meghan E. Sise   +2 more
doaj   +1 more source

A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients

Respiratory Medicine Case Reports, 2021
Background: Immune checkpoint inhibitor therapy is rapidly becoming front line adjuvant or primary therapy in a number of solid cancer types. Since many of these cancers are a result of tobacco smoking, a large number of these patients will have ...
Viswam S. Nair, Keith Eaton, A. McGarry Houghton   +2 more
doaj   +1 more source

Pembrolizumab related Guillain barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer

Journal of Community Hospital Internal Medicine Perspectives, 2021
Immune checkpoint inhibitor-related neurotoxicity causing Guillain Barre Syndrome is relatively uncommon. We discussed an 80-year-old patient with known systemic lupus erythematosus who presented with lower extremity weakness, areflexia and then ...
Vikram Sangani, Mytri Pokal, Mamtha Balla, Ganesh Prasad Merugu, Sreedhar Adapa, Srikanth Naramala, Venu Madhav Konala   +6 more
doaj   +1 more source

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Checkpoint inhibitor therapies are members of a new, groundbreaking class of drugs that reinvigorate the immune system to directly attack tumors.
Amulya Balagani, Muhammad H Arain, Ajay Sheshadri   +2 more
doaj   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis

Frontiers in Oncology, 2021
BackgroundThe published evidence from several randomized controlled clinical trials of immunotherapy for advanced esophageal squamous cell carcinoma has shown promising results. This study aimed to investigate the efficacy and safety of immune checkpoint
Yi-Min Gu, Qi-Xin Shang, Yue Zhuo, Jian-Feng Zhou, Bo-Wei Liu, Wen-Ping Wang, Guo-Wei Che, Long-Qi Chen   +7 more
doaj   +1 more source